Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better
Article first published online: 12 FEB 2014
© 2014 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 276, Issue 3, pages 243–247, September 2014
How to Cite
Kronenberg, F. (2014), Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better. Journal of Internal Medicine, 276: 243–247. doi: 10.1111/joim.12207
- Issue published online: 12 AUG 2014
- Article first published online: 12 FEB 2014
- Accepted manuscript online: 26 JAN 2014 08:05AM EST
- German Ministry of Education and Research (BMBF). Grant Number: 01ER0804
- KfH Foundation for Preventive Medicine
- Austrian National Bank
- Austrian Genome Project ‘GEN-AU’
- 11AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013; 128: 962–9., , et al.
- 16Impact of Lp(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med (in press)., , et al.
- 20Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol (in press)..
- 24The mysterious lipoprotein(a) is still good for a surprise. Lancet Diabetes Endocrinol 2013; 1: 170–2., .